Cart
sales@molnova.com
JNJ-7706621
CAS No. 443797-96-4
JNJ-7706621 ( JNJ7706621;JNJ 7706621 )
Catalog No. M14517 CAS No. 443797-96-4
A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 55 | In Stock |
|
| 5MG | 96 | In Stock |
|
| 10MG | 170 | In Stock |
|
| 25MG | 268 | In Stock |
|
| 50MG | 492 | In Stock |
|
| 100MG | 690 | In Stock |
|
| 500MG | 1395 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ-7706621
-
NoteResearch use only, not for human use.
-
Brief DescriptionA dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
-
DescriptionA dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM), and no activity for Plk1 or Wee1; arrests the cell cycle at the G2-M phase; shows significant antitumor activity in tumor xenograft model.
-
SynonymsJNJ7706621;JNJ 7706621
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorAuroraA;AuroraB;CDK1/CyclinB;CDK2/CyclinA;CDK2/CyclinE
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number443797-96-4
-
Formula Weight394.36
-
Molecular FormulaC15H12F2N6O3S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O
-
Chemical NameBenzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Emanuel S, et al. Cancer Res. 2005 Oct 1;65(19):9038-46.
2. Huang S, et al. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
3. Seamon JA, et al. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
2. Huang S, et al. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
3. Seamon JA, et al. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
molnova catalog
related products
-
LY-3177833
A potent and selective CDC7 inhibitor with IC50 of 3.3 nM.
-
Compound 919278
Compound 919278 is a specific inhibitor of lymphotoxin β receptor (LTβR, IC50=0.169 uM).
-
PF-06873600
PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
